FIGO 2018 Staging for Cervical Cancer: Influence on Stage Distribution and Outcomes in the 3D-Image-Guided Brachytherapy Era
| Autor: | Shin-ei Noda, Daisuke Irie, Takuya Kumazawa, Takuya Kaminuma, Kento Tomizawa, Takahiro Oike, Tatsuya Ohno, Kazutoshi Murata |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
Oncology
Cancer Research medicine.medical_specialty medicine.medical_treatment Brachytherapy outcomes FIGO 2018 staging system lcsh:RC254-282 Article 03 medical and health sciences 0302 clinical medicine Internal medicine medicine Distribution (pharmacology) Stage (cooking) Definitive radiotherapy radiotherapy Cervical cancer 030219 obstetrics & reproductive medicine business.industry image-guided brachytherapy medicine.disease lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens Radiation therapy 3d image 030220 oncology & carcinogenesis T-stage business uterine cervical cancer |
| Zdroj: | Cancers, Vol 12, Iss 1770, p 1770 (2020) Cancers Volume 12 Issue 7 |
| ISSN: | 2072-6694 |
| Popis: | Recent widespread use of three-dimensional image-guided brachytherapy (3D-IGBT) has improved radiotherapy outcomes of cervical cancer dramatically. In 2018, the International Federation of Gynecology and Obstetrics (FIGO) staging system for cervical cancer was revised. However, the influence of the revisions on the stage distribution and outcomes of cervical cancers treated with 3D-IGBT remains unclear. Here, we retrospectively analyzed 221 patients with cervical squamous cell carcinoma treated with definitive radiotherapy using 3D-IGBT (median follow-up, 60 months). The stage distribution and outcomes were compared between the 2009 and 2018 schemas. Stage migration occurred in 52.9% of the patients. Patients classified with the 2018 criteria as stage IIICr had the highest proportion (43.8%) of migration, and were mainly from the 2009 stages IIB and IIIB. The 2009 and 2018 schemas showed comparable performance at stratifying 5-year overall survival (OS) and 5-year progression-free survival (PFS) for patients in stages IB&ndash IVA. The 2018 criteria effectively stratified 5-year OS and PFS in the stage III substages. The 5-year OS and PFS for stage IIIC1r patients varied according to tumor T stage. These data provide evidence for the utility of the revised 2018 FIGO staging system in the clinical management of cervical cancers in the 3D-IGBT era. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|